|Bid||5.74 x 1800|
|Ask||5.75 x 1400|
|Day's Range||5.47 - 5.85|
|52 Week Range||5.30 - 18.55|
|Beta (5Y Monthly)||1.56|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2024 - Mar 01, 2024|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.60|
Subscribe to Yahoo Finance Plus to view Fair Value for NVAX
Biotech company Novavax (NASDAQ: NVAX) went from being relatively unknown just four years ago to becoming one of the U.S. COVID-19 vaccine market leaders. The company has faced many trials and tribulations in this period, however. If Novavax can mount a comeback, now may be as good a time as any to press the buy button while its shares are changing hands for just about $5.46 apiece.
Market performance hangs on U.S. vaccination rates for these three companies.
Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.